Actively Recruiting
Study of BOLD-100 Combined With FOLFOX Chemotherapy With or Without Bevacizumab for Advanced Gastrointestinal Cancers
Led by Bold Therapeutics, Inc. · Updated on 2026-10-28
220
Participants Needed
28
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating BOLD-100, an intravenous ruthenium-based small molecule drug, in combination with FOLFOX chemotherapy with or without Bevacizumab for treating advanced gastrointestinal cancers such as colorectal, pancreatic, gastric cancers, and cholangiocarcinoma. This Phase 1b2a non-randomized study includes a dose escalation phase to assess safety and tolerability, followed by a cohort expansion phase focusing on patients with advanced solid tumors. The study aims to understand BOLD-100s potential when combined with standard chemotherapy regimens. Participants receive BOLD-100 combined with FOLFOX chemotherapy, with or without Bevacizumab, in different dose levels including 500 mgm2 and 625 mgm2. The study includes multiple arms, some closed to enrollment and others open to patients with colorectal cancer who are oxaliplatin naive and have had only one prior metastatic treatment. Participants are randomized in Arm VII to receive one of two doses of BOLD-100 plus FOLFOX Bevacizumab or FOLFOX Bevacizumab alone. Throughout the study, participants undergo assessments for adverse events, dose-limiting toxicities, physical exams, ECGs, laboratory tests, and performance status. Quality of life questionnaires focusing on general and neuropathy-related aspects are completed by those in Arm VII. Researchers measure progression-free survival, overall response rate, and overall survival. The study also monitors pharmacokinetics and biomarkers during treatment. Participation continues until approximately two weeks after the last treatment, with ongoing safety and efficacy evaluations.
CONDITIONS
Brief Title
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
Research Team
M
Michelle Jones
J
Jim Pankovich
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here